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peak exercise but also at the second and fourth minute of effort (p < 0.03
and p < 0.01, respectively) resulting in a more gradual HR increase during
the first phases of effort. No major side effect occurred.
In conclusion in pts. with stable AF propafenone is able to achieve a sig-
nificant control of HR increase during effort, probably by virtue of its slight
beta-blocking effect. Moreover the combination of D + P results in an addi-
tive effect with a better control of HR during effort.
Continuous Infusion of Prostacyclln (PGIz)
Improves Survival in Severe Pulmonary
Hypertension
A. Yazdani Butt, George Cremona, Linda Sharples, Tim W. Higenbottam. Papworth
Hospital Cambridge, England, UK
In primary pulmonary hypertension PGI2, when added to conventional ther-
apy, enhances early survival at 3 months and improves exercise tolerance
(Long et ai, Am Rev Respir Dis 1993; 149: A538). High dose Ca++ channel
blockers may improve survival in mild to moderate disease (Rich et ai, N Eng
J Med 1992; 327: 76-81). We have compared the effect of continuous infu-
sion of PGI2 on survival of 114 patients with pulmonary hypertetion where
severity of disease was determined by a mixed venous oxygen saturation
(Sv02)' Patients were categorized into groupl ISv02 2: 60%) and group2
(Sv02 < 60%) at diagnostic right heart catheterization. Majority of patients
had primary pulmonary hypertension In = 90) while others had thromboem-
bolic disease (n = 24). 67 patient were treated with PGI2, while 47 patients
were treated with conventional therapy (CT) ie. anticoagulants with or with-
out oral vasodilators. End point of the study was either death or heart-lung
transplantation.
tration. In conclusion, BPS could provide a favorable remedy in the treatment
of patients with PH.
Diuretic Therapy Improves Exercise Capacity in
Patients with Angina but has no Effect on Nitrate
Tolerance
John D. Parker, Andrea B. Parker, Bernice Farrel, John O. Parker. Kingston General
Hospital, Kingston, and Mount Sinai Hospital, Toronto, Ontario, Canada
Diuretics have been reported to prevent tolerance to the organic nitrates.
Since diuretic therapy itself may have an anti-anginal effect, we carried out
a study which examines the effect of diuretic therapy alone on exercise ca-
pacity in angina as well as its effect on nitrate tolerance.
Methods. 12 patients with stable angina were studied. All had normal LV
systolic function. None were hypertensive or had a history of CHE Patients
received a diuretic (HCTZ plus amiloride) or placebo for 10-14 days in a ran-
domized, double-blind, cross-over trial. During the last 5-7 days of each treat-
ment period they received continuous transdermal nitroglycerin (TGTN) 0.8
mglhr in a single blind manner. Treadmill walking time (TWTl was assessed
prior to the addition of TGTN (Day 1) to assess the effect of diuretic alone,
on the first day of TGTN therapy (Day 2) and on the last day of TGTN therapy
(Day 3). Exercise testing was performed at 0800, 1200 and 1600 hrs on each
of these days.
Results. Diuretic therapy caused an increase in TWT on all 3 study days.
HR and systolic BP were higher at peak exercise during diuretic therapy as
compared to placebo (data not shown). Diuretic therapy did not prevent the
development of tolerance during continuous TGTN therapy.
Mean (Inter-quartile rangel. *P < 0.05, Likelihood ratio test
Continuous PGl2 infusion, in comparison to CT, improved median survival
in patients with severe pulmonary hypertension who had Sv02 of less than
60%. However in moderate disease with Sv02 of 2: 60%, PGl2 had no ad-
vantage over CT. Continuous long term PGl2 may be a useful treatment in
selected patients with pulmonary hypertension where Sv02 is less than 60
percent.
5..
.
1 I I~ I ] I .r II 5! If I :.I.it:
• I 't '! ':l!J 5! !!J -. • dJ"reUc therapy
=
_ placebo .erapy
.,.,., ...,.,. ..,.y~
Tuesday, March 21, 1995, Noon-2:00 p.m.
Ernest N. Morial Convention Center, Hall E
Presentation Hour: Noon-1 :00 p.m.
Myocardial Adaptation in Heart Failure: Basic
*p = < 0.05 vs placebo (cross over analysis of Hills and Armitage).
Conclusions. Diuretic therapy has significant anti-anginal effects and im-
proves exercise capacity in patients with stable angina. Diuretics appear to
have no effect on the development of tolerance to continuous TGTN therapy
as assessed by treadmill exercise testing.
CT (n ~ 17) PGI2 (n ~ 39)
Sv02 < 60% In = 56)
253 666*
(30--570) (240--1470)
Group 2 (n = 56): Sv02 < 60%
35.1 ± 12.7
31/25
677 ± 15.5*
13.1 ± 5.8*
51.2 ± 7.2*
1.79 ± 0.46*
CT (n = 30) PGI2 (n = 261
1277 1061
(390->2100) (450--1590)
Group 1(n = 581: Sv02 '" 60%
39.1 ± 11.8
39/19
59.9 ± 15.6
8.5 ± 63
67.4 ± 6.1
2.05 ± 0.67
Beneficial Effects of Beraprost Sodium in
Patients with Pulmonary Hypertension
Sv02 2: 60% In = 581
Mean ± SO, *p < 0.05
Age (Y)
Sex FIM
PAPm(mmHg)
RAPm(mmHg)
Sv02 (%)
CI (Umin/m 2)
Median
survival in days
1965-46 1
Yasunori Nakayama, Yoshiaki Okano, Toru Satoh, Akito Shimouchi,
Takeyoshi Kunieda. Division of Cardiology, Department of Internal Medicine, National
Cardiovascular Center, Suita, Osaka. Japan
Intravenous infusion of prostacyclin (PGI2) is considered to be one of the
most effective vasodilating remedy in patients with pulmonary hypertension
(PH). To determine whether beraprost sodium (BPS), a oral PGI2 derivative,
clinically available in Japan, is also effective in PH. We selected 11 patients
(3 males, 8 females, 42 ± 13 years old) with moderate to severe PH (NYHA
II I'" IV) dueto primary or inoperable thromboembolic PH. Hemodynamic mea-
surements by means of cardiac catheterization were performed before and
immediately after single dose of oral BPS (60-100 JLg). and restudied after 1
to 2 months of chronic administration (20-40 JLg, t.i.d.l.
Results: (1) Acute effects; There were significant decrease in mean pul-
monary artery pressure (PAm) (70 ± 13-+55 ± 12 mmHg, p < 0.01) and total
pulmonary resistance (TPR) (19.9 ± 10.6-+ 16.8 ± 11.7 u, p < 0.05). and in-
crease in cardiac output (CO) (3.0 ± 1.1-+3.5 ± 1.7 I/min, p < 0.05) at the
maximum effects. TPR decreased more than 20% in 5 of 11 patients. There
were also slight but not significant decrease in mean systemic blood pres-
sure (SAm)(81 ± 10to 73 ± 4 mmHg)taken as a whole, but obviously fell in 3
patients more than 30%. (2) Chronic effects; PAm (47.5 ± 7 mmHg) and TPR
(14.1 ± 3.4 u) significantly decreased, and CO (3.5 ± 0.8I/min) significantly
increased compared with baseline values. TPR decreased more than 20%
in all but one patient. SAm (81 ± 8 mmHg) were not significantly reduced,
and did not fall more than 20% in any patient. All patients are alive and in
better conditions during 12.1 ± 6.1 months follow up with chronic adminis-
Survival After Large Myocardial Infarction in Rats:
Comparison of ACE Inhibition with Captopril
Versus Direct Angiotensin 1\ Blockade with
Losartan
James J. Milavetz, Thomas E. Raya, Eugene Markin, Steven Goldman. Veterans
Administration Medical Center and University ofArizona Heart Center, Tucson, AZ
To compare the effects of angiotensin converting enzyme (ACE) inhibition
vs angiotensin II (A-II) receptor blockade on survival, rats with large myocar-
dial infarctions were treated with captopril (N = 46) or losartan (N = 51) a
specific A-II antagonist, at a dose of 2 gIL drinking water. Therapy was initi-
ated immediately after coronary artery ligation and continued for one year.
Median survival in captopril treated rats was 191.4 ± 14.1 days vs 246.4 ±
15.7 days for losartan treated rats (P < 0.03). Measurements of myocardial
function and LV geometry were obtained at one year in surviving rats (N =
5 for captopril; 9 for losartan). No differences were noted in heart weight,
LV pressures, dPldt, cardiac index, time constant of relaxation, or LV volume
and dimensions. In losartan-treated rats, however, heart rate was increased
1293 ± 19 vs 266 ± 15 beatslmin, P < 0.05) and peak developed pressure
was decreased (153 ± 21 vs 180 ± 16 mmHg, P < 0.05). Thus, in the rat
model of heart failure, survival was prolonged with losartan compared to
captopril, suggesting that the major benefit of ACE inhibition is attenuation
of responses mediated through the A-II receptor.
